113 related articles for article (PubMed ID: 18447209)
21. Doripenem (Doribax): the newest addition to the carbapenems.
Greer ND
Proc (Bayl Univ Med Cent); 2008 Jul; 21(3):337-41. PubMed ID: 18628935
[TBL] [Abstract][Full Text] [Related]
22. Single-Center Pharmacokinetic Study and Simulation of a Low Meropenem Concentration in Brain-Dead Organ Donors.
Lee JM; Lee JW; Jeong TS; Bang ES; Kim SH
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061281
[TBL] [Abstract][Full Text] [Related]
23. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.
Antonello RM; Di Bella S; Maraolo AE; Luzzati R
Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1117-1126. PubMed ID: 33604721
[TBL] [Abstract][Full Text] [Related]
24. First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects.
Huang Z; Yang X; Jin Y; Yu J; Cao G; Wang J; Hu Y; Dai J; Wu J; Wei Q; Tian Y; Yu S; Zhu X; Mao X; Liu W; Liang H; Zheng S; Ju Y; Wang Z; Zhang J; Wu X
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0133023. PubMed ID: 38054726
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis.
Ullah S; Ursli M; Fuhr U; Wiesholzer M; Kussmann M; Poeppl W; Zeitlinger M; Taubert M
Perit Dial Int; 2023 Sep; 43(5):402-410. PubMed ID: 37131320
[TBL] [Abstract][Full Text] [Related]
26. Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
Liu Y; Moodley M; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0140122. PubMed ID: 36877034
[TBL] [Abstract][Full Text] [Related]
27. Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with
Nakashima H; Miyazaki M; Kuwamura T; Oda K; Haga Y; Imakyure O
Antibiotics (Basel); 2024 Feb; 13(3):. PubMed ID: 38534654
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics/pharmacodynamics cut-off determination for fosfomycin using Monte Carlo simulation in healthy horses.
Kuroda T; Minamijima Y; Niwa H; Mita H; Tamura N; Fukuda K; Toutain PL; Ohta M
J Vet Med Sci; 2024 Apr; 86(4):413-420. PubMed ID: 38346727
[TBL] [Abstract][Full Text] [Related]
29. Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria.
Fresán D; Luque S; Benítez-Cano A; Sorlí L; Montero MM; De-Antonio M; Vega V; Roberts JA; Horcajada JP; Grau S
J Antimicrob Chemother; 2023 Dec; 78(12):2810-2815. PubMed ID: 37823445
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients.
Alsultan A; Aldawsari MR; Alturaiq NK; Syed SA; Alsubai A; Kurdee Z; Alsubaie S; Alqahtani S; Abouelkheir M
Pediatr Neonatol; 2024 Jan; ():. PubMed ID: 38218717
[TBL] [Abstract][Full Text] [Related]
31. Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections.
Maranchick NF; Webber J; Alshaer MH; Felton TW; Peloquin CA
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136730
[TBL] [Abstract][Full Text] [Related]
32. Predictors for non-attainment of meropenem target concentrations when treating infections in critically ill patients
.
Zheng SJ; Xu Y; Chen ND; Hao JW; Zhu Y; Jie Q
Int J Clin Pharmacol Ther; 2024 Jan; 62(1):1-7. PubMed ID: 37969092
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy.
Álvarez JC; Cuervo SI; Silva E; Díaz JA; Jiménez LL; Parra DS; Gómez JC; Sánchez R; Cortés JA
Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33946665
[TBL] [Abstract][Full Text] [Related]
34. Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption.
Reyes Barros T; Gutiérrez Torres W; García Cañete P; Cerda Lorca J
J Antimicrob Chemother; 2024 Apr; 79(4):774-778. PubMed ID: 38334363
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting.
Yang X; Jin L; Luo X; An S; Wang M; Zhu H; Zhou Y; Liu H
Ther Drug Monit; 2023 Dec; 45(6):786-791. PubMed ID: 37296502
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam.
Koumaki V; Dokoumetzidis A; Angelerou MGF; Baka S; Balakrishnan I; Tsakris A
Microbiol Spectr; 2023 Jan; 11(2):e0344122. PubMed ID: 36715534
[TBL] [Abstract][Full Text] [Related]
37. A mechanism-based pathway toward administering highly active N-phage cocktails.
Smith NM; Nguyen TD; Chin WH; Sanborn JT; de Souza H; Ho BM; Luong T; Roach DR
Front Microbiol; 2023; 14():1292618. PubMed ID: 38045026
[TBL] [Abstract][Full Text] [Related]
38. Usage of Meropenem Continuous Infusion for Treatment of Infectious Complications in Orthopedic Elderly Patients with Anemia: A Case Series.
Konkayev A; Kadralinova A; Azimova B; Tazhibayeva D; Yeltayeva A; Konkayeva M
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929546
[No Abstract] [Full Text] [Related]
39. Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials.
Ai MY; Chang WL; Liu CY
Front Microbiol; 2024; 15():1337570. PubMed ID: 38525074
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of prophylactic cefoxitin in elective bariatric surgery patients: a prospective monocentric study.
Novy E; Liu X; Hernández-Mitre MP; Belveyre T; Scala-Bertola J; Roberts JA; Parker SL
Anaesth Crit Care Pain Med; 2024 Jun; 43(3):101376. PubMed ID: 38494157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
